Loading...
Market
Will Google DeepMind announce a partnership with a major pharmaceutical company to use AlphaProteo by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Google DeepMind or the pharmaceutical company
Story
Google DeepMind Unveils AlphaProteo with 3-300x Better Binding Affinities
Sep 5, 2024, 03:24 PM
Google DeepMind has unveiled AlphaProteo, an advanced AI system designed to create novel proteins with high binding affinities. This system aims to revolutionize drug design and biological research by designing proteins that can effectively bind to target molecules. AlphaProteo has demonstrated 3-300 times better binding affinities and success rates compared to existing methods. The technology could significantly accelerate the understanding of biological processes and facilitate the development of more targeted, less side-effect treatments for diseases such as cancer and autoimmune disorders. Researchers at Isomorphic Labs and other institutions are eager to explore its applications in drug design and other fields. Additionally, AlphaFold is revolutionizing protein structure predictions, enabling the mapping of structural data for approximately 9000 Pfam protein families that lacked experimental structures.
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
